Pixium Vision announces business update and important forthcoming milestones to provide on its company system
- 1st individual productive implant activation in PRIMAvera pivotal EU review
- On monitor to report PRIMAvera details in early 2023 and post CE mark in H1 2023
- Aims to capitalize on improved desire from US traders
- Possibilities contains opportunity NASDAQ listing US Financial commitment bank hired
Paris, France, June 2, 2021 – 07.00 CET– Pixium Vision SA (Euronext Development Paris – FR0011950641), a bioelectronics business that develops innovative bionic eyesight systems to help sufferers who have dropped their sight to dwell extra independent life, supplies a complete enterprise update and announces an energetic exploration of quite a few selections to make certain the growth of the Prima Technique, which include a potential listing on the NASDAQ stock trade in the US, even though retaining its present most important listing on Euronext Expansion Paris.
Lloyd Diamond, CEO of Pixium Eyesight, commented “Pixium Eyesight has remained laser focused on its goals and has continued to provide on its guarantees, even with the challenging surroundings for the Firm and the over-all market by means of 2020 and the early months of 2021. The revolutionary Prima Technique for bionic eyesight proceeds to advance by clinical development with the PRIMAvera pivotal analyze possessing recently activated its very first implanted affected individual. Our fruitful discussions with US investors about the very last 6 months have indicated potent interest in Pixium Eyesight and its technology. To capitalize on these discussions and acquire an a lot easier obtain to US traders, Pixium Eyesight has hired a primary US investment bank to recommend on attainable solutions, such as the most effective route to a doable IPO on US NASDAQ. Accessing this significant expenditure pool will provide a incredible prospect to Pixium Eyesight to accelerate medical advancement and get ready for the professional start of Prima Process in late 2023.“
PRIMAvera European pivotal trial – On monitor for CE Mark submission in H1 2023
The pivotal PRIMAvera medical trial is under way with the 1st individual enrolled and implanted. The first implanted patient was not too long ago activated and the teaching phase has been initiated. Patients continue on to be screened and the study continues to be on monitor to report facts early 2023 for a CE Mark submission in Europe in H1 2023, main to a potential European acceptance in late 2023.
Prima System in the US – Feasibility review ongoing – information envisioned in H2 2022
In the US, the early feasibility research is ongoing with data anticipated in H2 2022. Although conversations have slowed owing to the COVID-19 pandemic, Pixium Eyesight is hopeful of getting more visibility on this procedure in direction of the conclusion of 2021. Should really the info generated by PRIMAvera be recognized by the Fda as adequate to file for regulatory approval, an Food and drug administration submission could consider put sooner than envisioned.
US NASDAQ listing regarded as – US Financial commitment bank employed
Accessing the US current market is a key priority and could carry major rewards to Pixium Vision, by broadening physical and economic existence in this essential current market. There has been improved interest from US buyers in Pixium Eyesight and its technological innovation in the final 6 months. In order to aid this curiosity, Pixium Vision’s Board of Administrators has determined to analyze the numerous options, together with a potential listing on the US NASDAQ stock exchange, and has employed a foremost US Expenditure lender to recommend on this system.
Subsequent Second Sight’s conclusion to unilaterally terminate the prepared small business mix, Pixium Eyesight has attempted to get to widespread arrangement exterior courtroom but 2nd Sight has failed to respond. To defend the interest of its shareholders, Pixium Vision submitted a legal action in France versus 2nd Sight. As with any ongoing legal continuing, Pixium Vision will update the marketplace anytime legally essential.
About Pixium Eyesight
Pixium Vision is generating a entire world of bionic vision for all those who have dropped their sight, enabling them to get back visible perception and bigger autonomy. Pixium Vision’s bionic vision units are connected with a surgical intervention and a rehabilitation period of time. Prima System sub-retinal miniature photovoltaic wi-fi implant is in scientific tests for patients who have lost their sight because of to outer retinal degeneration, at first for atrophic dry age-linked macular degeneration (dry AMD). Pixium Eyesight collaborates carefully with academic and investigate associates, such as some of the most prestigious eyesight exploration establishments in the earth, these kinds of as: Stanford University in California, Institut de la Eyesight in Paris, Moorfields Eye Medical center in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University medical center in Bonn, and UPMC in Pittsburgh, PA. The organization is EN ISO 13485 qualified and qualifies as “Entreprise Innovante” by Bpifrance.
For much more information: http://www.pixium-vision.com/fr
Observe us on @PixiumVision www.fb.com/pixiumvision
Chief Fiscal Officer
+33 1 76 21 47 68
Guillaume van Renterghem
+41 76 735 01 31
- 2021-05-28-Pixium_Enterprise Update_Vdef